Intra-Cellular Therapies (NASDAQ:ITCI) was downgraded by equities researchers at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Tuesday.

Other equities analysts also recently issued reports about the stock. Cantor Fitzgerald reiterated a “buy” rating on shares of Intra-Cellular Therapies in a research note on Wednesday, August 9th. Zacks Investment Research upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Tuesday, August 15th. Cowen reiterated a “buy” rating and set a $20.00 price objective on shares of Intra-Cellular Therapies in a research note on Wednesday, August 23rd. BTIG Research reiterated a “buy” rating and set a $36.00 price objective on shares of Intra-Cellular Therapies in a research note on Friday, September 8th. Finally, SunTrust Banks upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research note on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $25.00.

Intra-Cellular Therapies (NASDAQ ITCI) traded down $0.10 during midday trading on Tuesday, hitting $14.82. 380,043 shares of the stock were exchanged, compared to its average volume of 682,032. Intra-Cellular Therapies has a 1 year low of $7.85 and a 1 year high of $22.67.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.53). Intra-Cellular Therapies had a negative net margin of 28,038.35% and a negative return on equity of 27.40%. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.06 million. During the same period last year, the firm earned ($0.70) earnings per share. The company’s quarterly revenue was up 675.0% on a year-over-year basis. analysts predict that Intra-Cellular Therapies will post -2.16 EPS for the current year.

In other news, major shareholder Alafi Capital Co Llc bought 258,065 shares of the stock in a transaction on Monday, October 2nd. The stock was bought at an average cost of $15.50 per share, for a total transaction of $4,000,007.50. Following the completion of the purchase, the insider now directly owns 3,953,270 shares in the company, valued at $61,275,685. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Sharon Mates sold 18,750 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $15.75, for a total transaction of $295,312.50. Following the completion of the sale, the chief executive officer now owns 1,107,457 shares of the company’s stock, valued at $17,442,447.75. The disclosure for this sale can be found here. 21.00% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. raised its holdings in shares of Intra-Cellular Therapies by 336.1% in the second quarter. Goldman Sachs Group Inc. now owns 580,770 shares of the biopharmaceutical company’s stock worth $7,213,000 after buying an additional 447,586 shares during the last quarter. Swiss National Bank raised its holdings in shares of Intra-Cellular Therapies by 31.0% in the third quarter. Swiss National Bank now owns 69,800 shares of the biopharmaceutical company’s stock worth $1,101,000 after buying an additional 16,500 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in shares of Intra-Cellular Therapies in the third quarter worth $390,000. First Midwest Bank Trust Division raised its holdings in shares of Intra-Cellular Therapies by 18.2% in the third quarter. First Midwest Bank Trust Division now owns 184,836 shares of the biopharmaceutical company’s stock worth $2,917,000 after buying an additional 28,487 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Intra-Cellular Therapies by 192.2% in the first quarter. Dimensional Fund Advisors LP now owns 124,622 shares of the biopharmaceutical company’s stock worth $2,025,000 after buying an additional 81,969 shares during the last quarter. 74.41% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/12/05/intra-cellular-therapies-itci-downgraded-by-valuengine.html.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.